Premium
Combination therapy of canine osteosarcoma with canine bone marrow stem cells, bone morphogenetic protein and carboplatin in an in vivo model
Author(s) -
Rici R. E. G.,
Will S. E. A. L.,
Luna A. C. L.,
Melo L. F.,
Santos A. C.,
Rodrigues R. F.,
Leandro R. M.,
Maria D. A.
Publication year - 2018
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12404
Subject(s) - carboplatin , mesenchymal stem cell , medicine , osteosarcoma , bone marrow , in vivo , chemotherapy , bone morphogenetic protein , cancer research , pathology , cisplatin , chemistry , biology , biochemistry , microbiology and biotechnology , gene
Osteosarcoma (OSA) is the most common malignant bone cancer in children and dogs. The therapeutic protocols adopted for dogs and humans are very similar, involving surgical options such as amputation. Besides surgical options, radiotherapy and chemotherapy also are adopted. However, hematologic, gastrointestinal and renal toxicity may occur because of chemotherapy treatments. Recent study clearly showed that mesenchymal stem cells (MSCs) combined with recombinant human bone morphogenetic protein (rhBMP‐2) may be associated with decreases of the tumorigenic potential of canine OSA. The aim of this study was to analyse the efficacy of chemotherapy with carboplatin and rhBMP‐2 with MSCs in a canine OSA in vivo model. Canine OSA cells were implanted in mice Balb‐c/nude with MSCs, rhBMP‐2 and carboplatin. Flow cytometry and PCR for markers involved in tumour suppression pathways were analysed. Results showed that the combination of MSCs and rhBMP‐2 reduced tumour mass and infiltration of neoplastic cells in tissues more efficiently than carboplatin alone. Thus it was demonstrated that the use of rhBMP‐2 and MSCs, in combination with conventional antineoplastic, may be an efficient treatment strategy.